|1.||Feldman, Steven R: 13 articles (12/2014 - 11/2002)|
|2.||van de Kerkhof, P C M: 12 articles (06/2015 - 02/2004)|
|3.||Kragballe, K: 12 articles (05/2014 - 01/2002)|
|4.||de Jong, E M G J: 7 articles (06/2015 - 10/2002)|
|5.||Ganslandt, Cecilia: 7 articles (01/2015 - 09/2008)|
|6.||Cambazard, F: 6 articles (05/2014 - 01/2002)|
|7.||Lebwohl, Mark: 6 articles (01/2013 - 11/2002)|
|8.||Ortonne, J P: 6 articles (08/2009 - 01/2002)|
|9.||Barnes, L: 5 articles (01/2009 - 04/2000)|
|10.||Rabasseda, X: 5 articles (09/2007 - 07/2004)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
07/01/2000 - "Given the greater safety and efficacy of combination regimens in terms of both short-term improvement and long-term control, initiating psoriasis treatment with a combination regimen of topical calcipotriene combined with an ultrapotent corticosteroid appears to be the most cost-effective approach to psoriasis treatment."
04/01/1994 - "At the end of the study period 60% of patients on calcipotriol showed clearance or marked improvement of their psoriasis compared with 17% on placebo. "
09/01/1996 - "Calcipotriol is effective in the treatment of psoriasis and it is an important addition to the therapeutic medications available to treat psoriasis. "
07/01/1994 - "Topical treatment of psoriasis with calcipotriol has been proven effective. "
01/01/2005 - "Topical Calcipotriol is an effective treatment for nail psoriasis and can be considered to be a safe topical treatment in chronic cases; its high tolerability allows prolonged usage without severe side effects."
09/01/2001 - "Topical calcipotriol appears to be an effective and well-tolerated treatment for vitiligo and can be safely used in conjunction with PUVA, but controlled studies are necessary to exclude the possibility of spontaneous repigmentation."
05/01/2003 - "Is the combination of calcipotriol and PUVA effective in vitiligo?"
03/01/2002 - "Topical calcipotriol in monotherapy is not an effective treatment of vitiligo."
03/01/2001 - "Calcipotriol is effective in certain keratinization disorders (ichtyoses) as well as in localized sclerodermia and vitiligo, although the effect is less certain for the latter conditions. "
05/01/2006 - "The aim of the present study was to compare the clinical efficacy of NB-UVB and NB-UVB plus topical calcipotriol in the treatment of vitiligo. "
03/01/2013 - "Incidence of adverse events in both treatment groups was low; calcipotriene foam, 0.005%, was associated with erythema. "
03/01/2013 - "Body involvement, target lesion score, and improvement for erythema, scaling, and plaque thickness were also assessed.<BR> At week 8, more subjects in the calcipotriene foam, 0.005% group (40.9%) met the primary end point vs the vehicle foam group (24.2%; intent-to-treat [ITT] population; P <.001); a significant difference between groups was also observed at weeks 2 (P = .041) and 4 (P <.001). "
02/01/2002 - "Calcipotriol for erythema annulare centrifugum."
06/01/2000 - "No difference in erythema was seen between calcipotriol medication and the vehicle controls. "
06/01/2000 - "Calcipotriol ointment and cream were applied in 19 and 18 subjects, respectively, and erythema was measured for each application time quantified. "
04/01/2007 - "Observation on local lesion showed that the scores of erythema, infiltration, scaly eruption, pruritus were significantly improved in difference between the CEBO group and the Daivonex group (P < 0.01). "
04/01/2007 - "The ITSI of pruritus was shorter in CEBO group than that in the Daivonex group and the placebo group (P < 0.01), but that of other symptoms showed insignificant difference between the CEBO group and the Daivonex group, as for comparing in ITSI of erythema, infiltration, scaly eruption and pruritus, it was significantly shorter in the CEBO group and Daivonex group than that in the placebo group respectively (P < 0.01). "
06/01/2004 - "Side effects reported were erythema (one patient) and increased pruritus (two patients), all with calcipotriol. "
12/01/2000 - "Considerable additional reductions (38%-50%) in overall severity of plaque psoriasis, plaque elevation, scaling, pruritus, and overall discomfort were achieved over and above improvements already achieved with calcipotriene therapy. "
01/01/2000 - "No significant adverse effects were reported in either group except in two patients (8.3%) in the calcipotriol group who developed signs of irritation including itching and erythema. "
01/01/2006 - "Our findings support previous reports of the utility of calcipotriene in treating other dermatoses as witnessed by the numerous conditions for which its use was observed. "
03/01/2003 - "Erosive pustular dermatosis of the scalp successfully treated with calcipotriol cream."
09/21/2011 - "Topical calcipotriol is an established mode of treatment for psoriasis and also reported to be effective in many hyperkeratotic skin diseases. "
01/01/2006 - "Primarily through regulation of cellular differentiation, calcipotriene may be effective in dermatoses other than psoriasis. "
01/01/2014 - "One example of such an analog with a good dissociation ratio is calcipotriol (Daivonex®), which is clinically used to treat the hyperproliferative skin disease psoriasis. "
|1.||betamethasone-17,21-dipropionate (betamethasone dipropionate)
|4.||calcipotriol drug combination betamethasone dipropionate
|6.||1 alpha,24-dihydroxyvitamin D3 (Tacalcitol)
|7.||Coal Tar (Estar)
|9.||Cholecalciferol (Vitamin D3)
|1.||Phototherapy (Light Therapy)
|3.||Day Care (Partial Hospitalization)